From Insight to Impact: Strategic Growth Mapping in the Age-Related Macular Degeneration Market
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Age-Related Macular Degeneration Market Growth Performance Trended Historically, And What Lies Ahead?
In recent times, the market size of age-related macular degeneration has witnessed significant expansion. The market, which is set to escalate from $9.96 billion in 2024 to $10.67 billion in 2025, is projected to experience a compound annual growth rate (CAGR) of 7.1%. The growth experienced in the historic period can be traced back to factors such as aging demographics, modifications in lifestyle and environmental conditions, genetic susceptibility as well as heightened awareness and early detection fueled by advances in diagnostic methods.
The market size of age-related macular degeneration is projected to witness significant growth in the upcoming years, rising to a sum of$14.29 billion by 2029 with a compound annual growth rate (CAGR) of 7.6%. The projected growth during the forecast period can be associated with advancements in the fields of genetics and biomarkers, the developing therapeutic models, the rise of telemedicine and remote monitoring, as well as patient advocacy and education. Key trends for the forecast period encompass the adoption of personalized medicine strategies, advancements in retinal imaging technologies, the development of sustained drug delivery systems, clinical trials for experimental therapies, and partnerships for research and development.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10845&type=smp
What are the Fundamental Drivers and Innovations Shaping the Age-Related Macular Degeneration Market?
The growth of the age-related macular degeneration (AMD) market is projected to be fueled by the increasing prevalence of AMD. Being a deteriorating eye condition, AMD affects the macula – the portion of the retina accountable for central vision. The treatments for AMD assist patients with retinal disorders by minimizing the severity of their condition. For instance, Optimaxa, a UK-based specialist in laser eye treatment, reported in February 2023 that global AMD affected 196 million individuals and is estimated to surge to 288 million in 2040, comprising 8.7 percent of the worldwide population. Consequently, the growing prevalence of age-related macular degeneration is propelling the AMD market.
How Is the Age-Related Macular Degeneration Market Segmented?
The age-related macular degenerationmarket covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration (AMD); Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea; Lucentis; Avastin; Other Products
3) By Route Of Administration: Intravenous; Intravitreal
4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy; Online Pharmacy
Subsegments:
1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections; Photodynamic Therapy; Laser Surgery
2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements; Low Vision Aids; Therapies For Geographic Atrophy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=10845&type=smp
Which Regions Are Driving the Next Phase of the Age-Related Macular Degeneration Market Growth?
North America was the largest region in the global age-related macular degeneration market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Key Trends Are Shaping the Future of the Age-Related Macular Degeneration Market?
Leading entities in the age-related macular degeneration (AMD) market are pioneering novel treatments like bispecific antibodies to decrease the frequency of treatments. Bispecific antibodies are specially crafted antibodies that can bind to two different antigens at the same time. For example, in May 2022, Chugai Pharmaceutical Co., Ltd., a pharmaceutical firm based in Japan, introduced Vabysmo intravitreal injection 120 mg/mL. This is a bispecific antibody developed for the treatment of eye ailments such as age-related macular degeneration (AMD) and diabetic macular edema (DME). This revolutionary treatment works by simultaneously targeting two vital pathways: angiopoietin-2 (Ang-2), which is implicated in abnormal blood vessel development and inflammation, and Vascular Endothelial Growth Factor-A (VEGF-A), a key element in the development of new blood vessels that can result in vision loss. Vabysmo touts extended dosing periods as a primary advantage, with treatments required every 16 weeks, improving patient comfort and compliance. Its dual-action strategy signifies a substantial milestone in eye treatments, effectively responding to the critical demand for dependable therapies in retinal diseases.
View the full report here:
How Is the Age-Related Macular Degeneration Market Defined and What Are Its Core Parameters?
Age-related macular degeneration (AMD) refers to a progressive eye condition in which the macula, which is located at the center of the retina, deteriorates over time in individuals with AMD, leading to a decline in central vision. It is due to aging. The therapy options for age-related macular degeneration include regular eye exams, lifestyle changes, and particular nutritional supplements.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10845
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
